Evidence map›Paper›PMID 36157282›Full record

ArticlePHAGE (New Rochelle, N.Y.)2022

Pathways to Phage Therapy Enlightenment, or Why I Have Become a Scientific Curmudgeon.

Stephen T Abedon

Abstract read
In one paragraph

Article in PHAGE (New Rochelle, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. How Simple Maths Can Inform Our Basic Understanding of Phage Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Stephen T AbedonDepartment of Microbiology, The Ohio State University, Mansfield, Ohio, USA.

Funding

The impact of bacteriophage therapy on wound infection dynamicsR01AI169865 · NIAID · OHIO STATE UNIVERSITY · PI Daniel J Wozniak · 2022 to 2026
$3.7M
Phage extracellular polysaccharide depolymerases to combat Pseudomonas aeruginosa biofilmsR21AI156304 · NIAID · OHIO STATE UNIVERSITY · PI ABEDON, STEPHEN T · 2021 to 2022
$429k
NIAID NIH HHS R01 AI169865NIAID NIH HHS R21 AI156304
6 · The paper itself

Abstract

Over the past decade I, with collaborators, have authored a number of publications outlining what in the first of these I described as "Phage therapy best practices"-phage therapy being the use of bacterial viruses (bacteriophages) to treat bacterial infections, such as clinically. More generally, this is phage-mediated biocontrol of bacteria, including of bacteria that can contaminate foods. For the sake of increasing accessibility, here I gather some of these suggestions, along with some frustrations, into a single place, while first providing by way of explanation where they, and I, come from scientifically. Although in my opinion phage therapy and phage-mediated biocontrol are both sound approaches toward combating unwanted bacteria, I feel at the same time that the practice of especially phage therapy research could be improved. I supply also, as supplemental material, a list of ∼100 English language 2000-and-later publications providing primary descriptions of phage application to humans.

Indexed as

antibacterialantibioticbacteriophage therapybiological control

Identifiers

PMID36157282
PMCPMC9436250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.